MedPath

Algipharma AS

Algipharma AS logo
🇳🇴Norway
Ownership
Private
Established
2006-08-01
Employees
11
Market Cap
-
Website
http://www.algipharma.com

Clinical Trials

17

Active:11
Completed:4

Trial Phases

2 Phases

Phase 1:12
Phase 2:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials

Phase 1
12 (75.0%)
Phase 2
4 (25.0%)

A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients with Cystic Fibrosis

Phase 2
Terminated
Conditions
Cystic Fibrosis
Interventions
Drug: OligoG DPI
First Posted Date
2019-01-30
Last Posted Date
2024-10-28
Lead Sponsor
AlgiPharma AS
Target Recruit Count
15
Registration Number
NCT03822455
Locations
🇦🇺

John Hunter Hospital, Newcastle, New South Wales, Australia

A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis

Phase 2
Withdrawn
Conditions
Cystic Fibrosis
Interventions
Drug: OligoG Dry powder for inhalation
First Posted Date
2018-10-09
Last Posted Date
2022-06-30
Lead Sponsor
AlgiPharma AS
Registration Number
NCT03698448
Locations
🇩🇪

CF Zentrum Köln, Universitätskrankenhaus Köln, Cologne, Germany

A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection

Phase 2
Completed
Conditions
Burkholderia Infection
Cystic Fibrosis
Interventions
First Posted Date
2015-05-27
Last Posted Date
2018-04-19
Lead Sponsor
AlgiPharma AS
Target Recruit Count
15
Registration Number
NCT02453789
Locations
🇩🇪

Pneumologische Praxis Pasing, Münich, Münich-Pasing, Germany

🇩🇪

Charité Universitätsmedizin Berlin, Berlin, Germany

A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis

Phase 2
Completed
Conditions
Cystic Fibrosis
Interventions
First Posted Date
2014-06-06
Last Posted Date
2018-04-19
Lead Sponsor
AlgiPharma AS
Target Recruit Count
65
Registration Number
NCT02157922
Locations
🇩🇰

Rigshospitalet, Copenhagen, Denmark

🇩🇪

Pediatric Pulmonology and Immunology, Charité Universitätsmedizin, Berlin, Germany

🇩🇪

CF Zentrum Köln, Universitätskrankenhaus Köln, Cologne, Germany

and more 15 locations

A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis

Phase 1
Completed
Conditions
Cystic Fibrosis
Interventions
First Posted Date
2011-11-04
Last Posted Date
2015-01-14
Lead Sponsor
AlgiPharma AS
Target Recruit Count
26
Registration Number
NCT01465529
Locations
🇮🇪

Beaumont Hospital, Dublin, Ireland

🇮🇪

University College Hospital Galway, Galway, Ireland

🇬🇧

Liverpool Heart & Chest Hospital, Liverpool, United Kingdom

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.